Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -1.05 is 11% below its 3-year average of -0.94, near the low end of its 3-year range (-1.26–-0.51).
14.29% above its 12-month average of -1.23.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.44.
EARNINGS PER SHARE (EPS)
-1.05
EARNINGS PER SHARE (EPS) AVG TTM
-1.23
EARNINGS PER SHARE (EPS) AVG 3Y
-0.94
EARNINGS PER SHARE (EPS) AVG 5Y
N/A
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+14.29%
CURRENT VS 3Y AVG
-11.11%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Aktis Oncology, Inc.
Market Cap
$969.98M
Earnings Per Share (EPS)
-1.05
TTM Avg
-1.23
3Y Avg
-0.94
5Y Avg
N/A
Market Cap
$976.29M
Earnings Per Share (EPS)
0.35
TTM Avg
-0.99
3Y Avg
-0.18
5Y Avg
0.61
Market Cap
$953.94M
Earnings Per Share (EPS)
-0.58
TTM Avg
-0.51
3Y Avg
-0.40
5Y Avg
-0.46
Market Cap
$987.62M
Earnings Per Share (EPS)
-2.97
TTM Avg
-9.41
3Y Avg
-6.16
5Y Avg
-6.16
Market Cap
$987.63M
Earnings Per Share (EPS)
0.71
TTM Avg
-1.77
3Y Avg
-1.98
5Y Avg
-1.86
Market Cap
$988.73M
Earnings Per Share (EPS)
-1.94
TTM Avg
-1.73
3Y Avg
-1.92
5Y Avg
-1.76
Market Cap
$997.02M
Earnings Per Share (EPS)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$942.38M
Earnings Per Share (EPS)
N/A
TTM Avg
-1.94
3Y Avg
-1.94
5Y Avg
-1.94
Market Cap
$1.00B
Earnings Per Share (EPS)
N/A
TTM Avg
-52.25
3Y Avg
-46.52
5Y Avg
-41.75
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aktis Oncology, Inc. (AKTS) | $969.98M | -1.05 | -1.23 | -0.94 | N/A |
| Pacira BioSciences, Inc. (PCRX)vs › | $976.29M | 0.35 | -0.99 | -0.18 | 0.61 |
| Savara Inc. (SVRA)vs › | $953.94M | -0.58 | -0.51 | -0.40 | -0.46 |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $987.62M | -2.97 | -9.41 | -6.16 | -6.16 |
| MeiraGTx Holdings plc (MGTX)vs › | $987.63M | 0.71 | -1.77 | -1.98 | -1.86 |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $988.73M | -1.94 | -1.73 | -1.92 | -1.76 |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $997.02M | N/A | N/A | N/A | N/A |
| Seaport Therapeutics, Inc. Common Stock (SPTX)vs › | $942.38M | N/A | -1.94 | -1.94 | -1.94 |
| Vor Biopharma Inc. (VOR)vs › | $1.00B | N/A | -52.25 | -46.52 | -41.75 |
| Kura Oncology, Inc. (KURA)vs › | $938.35M | -3.37 | -2.60 | -2.33 | -2.16 |
Trailing EPS (TTM)
$-1.05
Forward EPS (Est.)
$-1.79
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -1.19 |
| 2024-12-31 | -1.26 |
| 2023-12-31 | -0.82 |
| 2022-12-31 | -0.51 |
